BE2016C058I2 - - Google Patents

Download PDF

Info

Publication number
BE2016C058I2
BE2016C058I2 BE2016C058C BE2016C058C BE2016C058I2 BE 2016C058 I2 BE2016C058 I2 BE 2016C058I2 BE 2016C058 C BE2016C058 C BE 2016C058C BE 2016C058 C BE2016C058 C BE 2016C058C BE 2016C058 I2 BE2016C058 I2 BE 2016C058I2
Authority
BE
Belgium
Prior art keywords
factor
analog
chimeric protein
factor vii
viia
Prior art date
Application number
BE2016C058C
Other languages
English (en)
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33452235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2016C058(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Publication of BE2016C058I2 publication Critical patent/BE2016C058I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BE2016C058C 2003-05-06 2016-10-27 BE2016C058I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46883703P 2003-05-06 2003-05-06
EP09004646A EP2077121B1 (fr) 2003-05-06 2004-05-06 Fusions protéiques chimères de facteur VII-Fc dans le traitement de maladies hémostatiques
EP04751357.7A EP1624891B2 (fr) 2003-05-06 2004-05-06 Proteines chimeriques a facteur de coagulation-region constante (fc) destinees au traitement de l'hemophilie

Publications (1)

Publication Number Publication Date
BE2016C058I2 true BE2016C058I2 (fr) 2023-08-09

Family

ID=33452235

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2016C058C BE2016C058I2 (fr) 2003-05-06 2016-10-27

Country Status (18)

Country Link
US (6) US20050147618A1 (fr)
EP (5) EP2298347B1 (fr)
AT (2) ATE497783T1 (fr)
AU (2) AU2004239244C1 (fr)
BE (1) BE2016C058I2 (fr)
CA (1) CA2522859C (fr)
CY (4) CY1109640T1 (fr)
DE (2) DE602004031390D1 (fr)
DK (3) DK2298347T3 (fr)
ES (3) ES2558102T3 (fr)
FR (1) FR16C0041I2 (fr)
HU (2) HUE026384T2 (fr)
LU (1) LU93265I2 (fr)
NL (1) NL300835I2 (fr)
PL (3) PL2077121T3 (fr)
PT (3) PT1624891E (fr)
SI (3) SI2298347T1 (fr)
WO (1) WO2004101740A2 (fr)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
EP1615945B1 (fr) 2003-04-09 2011-09-28 BioGeneriX AG Methode de glycopegylation et proteines/peptides produits au moyen de ces methodes
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
PT1624891E (pt) 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005012484A2 (fr) 2003-07-25 2005-02-10 Neose Technologies, Inc. Conjugues anticorps-toxines
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
JP2007531513A (ja) 2003-11-13 2007-11-08 ハンミ ファーム．インダストリー カンパニー リミテッド 薬物のキャリアとして有用なＩｇＧＦｃ断片およびその製造方法
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
WO2006010143A2 (fr) 2004-07-13 2006-01-26 Neose Technologies, Inc. Remodelage de peg ramifie et glycosylation de peptide-1 semblable a glucagon [glp-1]
EP1814573B1 (fr) 2004-10-29 2016-03-09 ratiopharm GmbH Remodelage et glycopegylation du facteur de croissance des fibroblastes (fgf)
CA2593682C (fr) 2005-01-10 2016-03-22 Neose Technologies, Inc. Facteur de stimulation de colonie de granulocytes glycopegylatees
SG158919A1 (en) 2005-01-24 2010-02-26 Univ Texas Constructs binding to phosphatidylserine and their use in disease treatment
EP1871795A4 (fr) 2005-04-08 2010-03-31 Biogenerix Ag Compositions et méthodes utilisées pour la préparation de mutants par glycosylation de l'hormone de croissance humaine résistant à la protéase
BRPI0608170A2 (pt) 2005-04-28 2010-11-09 Novo Nordisk Healthcare Ag recipiente fechado contendo uma composição de um polipeptìdeo do fator vii ativado, processo para a preparação de um recipiente fechado contendo um polipeptìdeo do fator vii ativado, kit, e, método para a preparação de uma composição farmacêutica
JP5335422B2 (ja) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (fr) 2005-11-03 2007-05-18 Neose Technologies, Inc. Purification de sucre de nucleotide en utilisant des membranes
EP1816201A1 (fr) * 2006-02-06 2007-08-08 CSL Behring GmbH Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée
HRP20160990T1 (hr) * 2006-03-24 2016-10-07 Biogen Hemophilia Inc. Pc5 kao enzim obrade faktor ix propeptida
KR20090013816A (ko) 2006-05-24 2009-02-05 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
EP1867660A1 (fr) 2006-06-14 2007-12-19 CSL Behring GmbH Protéine de fusion qui peut être clivée protéolyticalement et qui contient un facteur de la coagulation sanguine
PL2032607T5 (pl) 2006-06-14 2017-10-31 Csl Behring Gmbh Rozszczepialne proteolitycznie białko fuzyjne obejmujące czynnik krzepnięcia krwi
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
US8754194B2 (en) 2006-12-22 2014-06-17 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
EP1935430A1 (fr) * 2006-12-22 2008-06-25 CSL Behring GmbH Facteurs de coagulation modifiés avec une demi-vie in vivo prolongée
ES2753183T3 (es) 2007-02-12 2020-04-07 Csl Behring Gmbh Aplicación terapéutica de inhibidores de la proteasa de serina de tipo Kazal
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
WO2008154639A2 (fr) 2007-06-12 2008-12-18 Neose Technologies, Inc. Procédé amélioré pour la production de sucres de nucléotide
CN103497247A (zh) 2008-02-27 2014-01-08 诺沃—诺迪斯克有限公司 缀合的因子viii分子
DK2865760T3 (en) 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
CA2742817A1 (fr) 2008-11-20 2010-05-27 Biogen Idec Ma Inc. Inactivation de virus par l'arginine
WO2010096394A2 (fr) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Véhicules de médicaments à base de protéine marqués par aldéhyde et procédés d'utilisation
JP5739865B2 (ja) * 2009-03-24 2015-06-24 バイエル・ヘルスケア・エルエルシー 第ｖｉｉｉ因子変異体および使用の方法
HUE029454T2 (en) * 2009-11-13 2017-03-28 Grifols Therapeutics Inc Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
BR112012013502A2 (pt) * 2009-12-06 2017-01-10 Biogen Idec Hemophilia Inc "polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos".
EP2371857A1 (fr) 2010-04-01 2011-10-05 CSL Behring GmbH Inhibiteurs de facteur XII pour traiter la maladie de poumon interstitiel
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
SG10201913700SA (en) 2010-07-09 2020-03-30 Bioverativ Therapeutics Inc Factor ix polypeptides and methods of use thereof
ES2739503T3 (es) * 2010-07-09 2020-01-31 Bioverativ Therapeutics Inc Moléculas de cadena simple procesables y polipéptidos producidos usándolas
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2619228A1 (fr) 2010-09-22 2013-07-31 Novo Nordisk A/S Anticorps thérapeutiques anti-facteur viii
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
KR101853405B1 (ko) * 2010-10-20 2018-05-02 주식회사 티움바이오 인자 ｉｘ 활성을 갖는 융합 단백질
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
US9540438B2 (en) 2011-01-14 2017-01-10 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof
CA2828769A1 (fr) * 2011-03-02 2012-09-07 Novo Nordisk A/S Facteur de coagulation ciblant tlt-1 sur des plaquettes activees
EP2497489A1 (fr) 2011-03-09 2012-09-12 CSL Behring GmbH Inhibiteur du facteur XII pour le traitement de la pénombre ischémique cérébrale et l'ischémie d'autres organes
ES2646191T3 (es) 2011-03-09 2017-12-12 Csl Behring Gmbh Inhibidores de Factor XII para la administración con procedimientos médicos que comprenden contacto con superficies artificiales
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
DK2729161T3 (en) 2011-07-08 2019-04-08 Bioverativ Therapeutics Inc FACTOR VIII CHEMICAL AND HYBRID POLYPEPTIDES AND PROCEDURES FOR USE THEREOF
FI2734552T3 (fi) 2011-07-22 2025-02-12 Csl Behring Gmbh Monoklonaaliset anti-tekijä xii/xiia -vasta-aineet ja niiden käyttö
WO2013016454A1 (fr) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Dosages pour la surveillance de troubles hémostatiques
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
KR20140083035A (ko) 2011-10-18 2014-07-03 체에스엘 베링 게엠베하 인자 ｖｉｉｉ의 생체이용률을 증가시키기 위한 황산화 글리코사미노글리칸과 하이알루로니다제의 병용 사용
AU2012318292B2 (en) 2011-10-18 2015-08-20 Csl Limited Method for improving the stability of purified Factor VIII after reconstitution
KR20140083036A (ko) 2011-10-18 2014-07-03 체에스엘 베링 게엠베하 인자 ｖｉｉｉ의 생체이용률을 향상시키기 위한 황산화 글리코사미노글리칸의 용도
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
BR112014017111A8 (pt) * 2012-01-12 2018-05-15 Biogen Idec Inc métodos de redução de imunogenicidade contra o fator viii em indivíduos submetidos à terapia de fator viii
CN111499761A (zh) 2012-01-12 2020-08-07 比奥贝拉蒂治疗公司 嵌合因子viii多肽及其用途
EP2623110A1 (fr) 2012-01-31 2013-08-07 CSL Behring GmbH Inhibiteurs de facteur XII pour le traitement de troubles inflammatoires neurologiques
PL2814502T3 (pl) 2012-02-15 2018-02-28 Csl Behring Gmbh Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
EP2834259A4 (fr) 2012-04-02 2016-08-24 Moderna Therapeutics Inc Polynucléotides modifiés
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2858659B1 (fr) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Composés pro-coagulants
US10202595B2 (en) * 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
WO2014008480A2 (fr) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Lignée cellulaire exprimant des polypeptides de facteur viii à une seule chaîne et ses utilisations
AU2013290173B2 (en) 2012-07-11 2018-02-15 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
EP3970738A1 (fr) 2012-07-25 2022-03-23 Bioverativ Therapeutics Inc. Essai de surveillance de facteur sanguin et utilisations de celui-ci
HK1213521A1 (zh) 2012-09-25 2016-07-08 Bioverativ Therapeutics Inc. Fix多肽的應用
EP2908847B1 (fr) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Procédés d'utilisation d'une dose fixe d'un facteur de coagulation
EP2914293A4 (fr) 2012-10-30 2016-04-20 Biogen Ma Inc Procédés d'utilisation du polypeptide fviii
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
CA2894219C (fr) * 2012-12-10 2020-08-11 Vib Vzw Nouveaux inhibiteurs de l'interleukine-33
JP6636334B2 (ja) 2013-03-08 2020-01-29 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 遠隔虚血再灌流傷害の治療および予防
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
EP3666283B1 (fr) 2013-03-15 2022-06-08 Bioverativ Therapeutics Inc. Formulations de polypeptide de facteur viii
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
US20160166660A1 (en) 2013-06-28 2016-06-16 Csl Behring Gmbh Combination therapy using a factor xii inhibitor and a c-1 inhibitor
EP3048899B1 (fr) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. Procédés d'inactivation de virus sur colonne
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (fr) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucléotides codant pour un récepteur de lipoprotéines de faible densité
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
PH12016501323B1 (en) * 2014-01-10 2022-04-29 Bioverativ Therapeutics Inc Factor viii chimeric proteins and uses thereof
EP3123090A4 (fr) 2014-03-24 2017-12-13 Bioverativ Therapeutics Inc. Formulations de facteur ix lyophilisées
BR112016029624A2 (pt) 2014-06-18 2017-10-24 Csl Behring Gmbh terapia usando um inibidor do fator xii em um distúrbio neurotraumático
EP3164150B1 (fr) 2014-07-02 2020-11-04 CSL Behring Lengnau AG Facteur de von willebrand modifié
CN104292341B (zh) * 2014-10-11 2018-08-10 上海兴迪金生物技术有限公司 一种凝血八因子融合蛋白及其制备方法和用途
AU2015364396B2 (en) 2014-12-19 2018-08-09 Alkermes, Inc. Single chain Fc fusion proteins
KR20170125941A (ko) 2015-03-06 2017-11-15 체에스엘 베링 리컴비넌트 퍼실리티 아게 개선된 반감기를 갖는 변형된 폰 빌레브란트 인자
EP4089109A3 (fr) 2015-05-22 2023-03-01 CSL Behring Lengnau AG Procédés de préparation du facteur willebrand modifié
BR112017023785A2 (pt) 2015-05-22 2018-07-17 Csl Behring Recombinant Facility Ag polipeptídeos do fator de von willebrand truncados para tratar hemofilia
EP3184149A1 (fr) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotéine v soluble pour le traitement de maladies thrombotiques
DK3400238T3 (da) 2016-01-07 2021-07-26 CSL Behring Lengnau AG Muteret von willebrand faktor
RU2018128582A (ru) 2016-01-07 2020-02-11 Цсл Беринг Ленгнау Аг Мутированный укороченный фактор фон виллебранда
KR20230136687A (ko) 2016-04-06 2023-09-26 시에스엘 리미티드 죽상동맥경화증의 치료 방법
MY197302A (en) 2016-04-15 2023-06-12 Takeda Pharmaceuticals Co Method and apparatus for providing a pharmacokinetic drug dosing regimen
CN109071634A (zh) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 抗体偶联物及其制备和使用方法
EP3474884A4 (fr) 2016-06-22 2020-08-19 Alkermes, Inc. Compositions et méthodes permettant de moduler les propriétés immunostimulantes et anti-inflammatoires de l'il-10
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
SG11201903954WA (en) 2016-11-11 2019-05-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
US11814421B2 (en) 2016-11-11 2023-11-14 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia
CN110520149A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
WO2018102743A1 (fr) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
CN110248964B (zh) 2017-02-01 2024-08-27 诺和诺德股份有限公司 促凝血抗体
CN110520152A (zh) * 2017-03-14 2019-11-29 俄亥俄州创新基金会 与靶向组织因子的igg3免疫缀合物有关的方法和组合物
WO2018234518A1 (fr) 2017-06-22 2018-12-27 CSL Behring Lengnau AG Modulation de l'immunogénicité de fviii par vwf tronqué
AU2018338608B2 (en) 2017-09-27 2025-09-11 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
BR112020018709A2 (pt) 2018-03-28 2021-01-05 Bristol-Myers Squibb Company Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso
MX2020010369A (es) 2018-04-04 2020-10-22 Sigilon Therapeutics Inc Particulas implantables y metodos relacionados.
WO2019195056A1 (fr) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Procédés, compositions et éléments implantables comprenant des cellules souches
JP7763589B2 (ja) 2018-05-18 2025-11-04 バイオベラティブ セラピューティクス インコーポレイテッド 血友病ａを処置する方法
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
US20220211808A1 (en) 2019-05-17 2022-07-07 Universitaet Zuerich Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke
KR20220029733A (ko) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
WO2021094344A1 (fr) 2019-11-11 2021-05-20 CSL Behring Lengnau AG Polypeptides pour induire une tolérance au facteur viii
PT4065585T (pt) 2019-11-25 2025-09-30 Alkermes Inc Compostos macrocíclicos substituídos e métodos de tratamento relacionados
WO2021154414A2 (fr) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Thérapie génique pour l'hémophilie b avec un vecteur de capside d'aav chimérique codant pour des polypeptides du facteur ix modifiés
EP4100426A1 (fr) 2020-02-06 2022-12-14 Bristol-Myers Squibb Company Il-10 et ses utilisations
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
IL302114A (en) 2020-10-29 2023-06-01 Bristol Myers Squibb Co Fusion proteins for the treatment of disease
CN116568327A (zh) 2020-11-20 2023-08-08 德国杰特贝林生物制品有限公司 治疗抗体介导的排斥反应的方法
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
KR20230142569A (ko) 2021-02-01 2023-10-11 체에스엘 베링 아게 출혈성 뇌졸중 후의 이차 신경학적 이상 반응을 치료 또는 예방하는 방법
CN117321074A (zh) 2021-05-07 2023-12-29 瑞士杰特贝林生物制品有限公司 用于产生重组触珠蛋白(Hp)β链的表达系统
KR20250058762A (ko) 2022-09-02 2025-04-30 체에스엘 베링 아게 과도한 발기 반응 또는 발기 부전을 치료하거나 예방하는 데 사용하기 위한 합토글로빈
CN120659872A (zh) 2022-10-11 2025-09-16 西吉隆医疗股份有限公司 用于治疗疾病的经工程化的细胞和可植入元件
WO2024081309A1 (fr) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Cellules modifiées et éléments implantables pour le traitement d'une maladie
WO2025257801A1 (fr) 2024-06-13 2025-12-18 CSL Innovation Pty Ltd Protéine de liaison à l'hème pour le traitement d'une lésion d'ischémie-reperfusion (iri)

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) * 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4456591A (en) * 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US5189015A (en) * 1984-05-30 1993-02-23 Alfa-Laval Agri International Ab Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability
US5077204A (en) 1984-06-21 1991-12-31 Chiron Corporation Yeast endopeptidase for basic amino-acid site cleavage, preparation and use
DK525384D0 (da) * 1984-11-05 1984-11-05 Nordisk Insulinlab Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5180583A (en) * 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
AU600575B2 (en) * 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
ZA89430B (en) 1988-01-22 1989-10-25 Gen Hospital Corp Cloned genes encoding ig-cd4 fusion proteins and the use thereof
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
JP2643968B2 (ja) 1988-02-03 1997-08-25 サントリー株式会社 Ｋｅｘ２エンドプロテアーゼ及びその製造方法
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2641468A1 (fr) 1989-01-11 1990-07-13 Merieux Inst Anticorps chimeriques anti-recepteur de l'interleukine-2 humaine, leur preparation et compositions pharmaceutiques les contenant
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
SE8901687D0 (sv) * 1989-05-11 1989-05-11 Alfa Laval Agri Int Fibronectin binding protein as well as its preparation
DE10399023I2 (de) * 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
GB9009106D0 (en) 1990-04-23 1990-06-20 3I Res Expl Ltd Processes and intermediates for synthetic antibody derivatives
DK0835939T3 (da) * 1990-06-28 2006-03-13 Sanofi Aventis Deutschland Fusionsproteiner med andele af immunglobulin, deres fremstilling og anvendelse
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0563214A4 (en) 1990-12-04 1994-08-17 Wistar Inst Bifunctional antibodies and method of preparing same
US5374617A (en) * 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
EP0636173B1 (fr) * 1991-05-31 1998-09-02 Genentech, Inc. Traitement du purpura thrombopenique immunitaire associe au virus vih
AU2795892A (en) * 1991-10-03 1993-05-03 Center For Blood Research, The Cd36 immunoadhesins and their use in selectively killing (plasmodium falciparum) infected erythrocytes
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
JP3490437B2 (ja) * 1992-01-23 2004-01-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 単量体および二量体抗体フラグメント融合タンパク質
CA2131003A1 (fr) * 1992-05-26 1993-12-09 Raymond G. Goodwin Nouvelle cytokine liant le cd30
AU5093593A (en) * 1992-08-28 1994-03-29 Scripps Research Institute, The Inhibition of tumor metastasis via neutralization of tissue factor function
GB2270845B (en) 1992-09-24 1996-07-10 Smiths Ind Med Syst Inc Suction catheter assemblies
US5563045A (en) * 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6518013B1 (en) * 1993-06-07 2003-02-11 Trimeris, Inc. Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US6310180B1 (en) * 1993-06-21 2001-10-30 Vanderbilt University Method for synthesis of proteins
US5648240A (en) * 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
WO1996010585A1 (fr) 1994-09-30 1996-04-11 Inex Pharmaceuticals Corp. Conjugues de proteines glycosylees/liposomes et leurs procedes de preparation
EP0805628B1 (fr) 1995-01-17 2003-05-02 Brigham And Women's Hospital, Inc. Transport transepithelial specifique de recepteurs d'immunogenes
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6036482A (en) † 1995-02-10 2000-03-14 Tokyo Electron Limited Heat treatment method
US5731168A (en) † 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5591573A (en) * 1995-04-10 1997-01-07 Alpha Therapeutic Corporation Method and system for testing blood samples
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) * 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5579277A (en) * 1995-05-01 1996-11-26 Apple Computer, Inc. System and method for interleaving memory banks
US6184344B1 (en) * 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
EP0831873A4 (fr) * 1995-06-07 2002-07-17 Trimeris Inc Therapie combinatoire pour le traitement d'infections virales vih et autres
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
CA2198968C (fr) 1996-03-04 2010-02-09 Toyofumi Masuda Procede de production de derives kex2 secretoires
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
IL130908A0 (en) * 1997-01-22 2001-01-28 Univ Texas Tissue-factor (tf) compositions for coagulation and tumor treatment
TW502011B (en) * 1997-02-05 2002-09-11 Ajinomoto Kk Process for producing n-long-chain acyl acidic amino acids or salts thereof
CA2225189C (fr) * 1997-03-06 2010-05-25 Queen's University At Kingston Gene et proteine du facteur viii du chien et methodes d'utilisation
WO1998056807A1 (fr) * 1997-06-13 1998-12-17 Gryphon Sciences Ligation chimique native en phase solide de peptides non proteges ou proteges en cysteine n-terminale dans une solution aqueuse
US6310183B1 (en) 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
PL199659B1 (pl) 1998-02-25 2008-10-31 Merck Patent Gmbh Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2
US6008321A (en) * 1998-03-16 1999-12-28 Pharmacopeia, Inc. Universal linker for combinatorial synthesis
US6281331B1 (en) * 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
WO1999059643A2 (fr) 1998-05-20 1999-11-25 Sdg, Inc. Complexe d'apport par liposomes
AU5728999A (en) 1998-07-28 2000-02-21 Micromet Ag Heterominibodies
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
CA2344764C (fr) 1998-09-30 2011-11-29 New England Biolabs, Inc. Ligation de peptide induite par une inteine
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP4463988B2 (ja) 1998-11-06 2010-05-19 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子の生産方法
US6280994B1 (en) * 1998-11-25 2001-08-28 Zymogenetics, Inc. Zace 1: a human metalloenzyme
CA2270600A1 (fr) 1999-05-03 2000-11-03 Infectio Recherche Inc. Methode et preparations pour le traitement de maladies, en particulier de celles causees par le virus de l'immunodeficience humaine et leishmania
DE60035871T2 (de) * 1999-05-19 2008-06-05 Merck Patent Gmbh Expression und export von interferon-alpha proteinen als fc fusionsproteine
AU775621B2 (en) 1999-07-01 2004-08-05 Yale University Neovascular-targeted immunoconjugates
WO2001002440A1 (fr) * 1999-07-02 2001-01-11 Genentech, Inc. Peptides de fusion comprenant un domaine ligand peptide et un domaine de multimerisation
IL147269A0 (en) * 1999-07-02 2002-08-14 Genentech Inc FVIIa ANTAGONISTS
US6469136B1 (en) * 1999-07-07 2002-10-22 Trimeris, Inc. Methods and composition for peptide synthesis
AU782496B2 (en) † 1999-07-13 2005-08-04 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
IL149202A0 (en) 1999-11-05 2002-11-10 Biogen Inc Hedgehog fusion proteins and uses
CA2391080A1 (fr) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Formes d'erythropoietine dotees de proprietes ameliorees
WO2001036637A1 (fr) 1999-11-17 2001-05-25 Immunex Corporation Activateur du recepteur de nf-kappa b
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
PL204285B1 (pl) 2000-02-11 2009-12-31 Bayer Healthcare Llc Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
DK1252192T3 (da) 2000-02-11 2006-11-20 Merck Patent Gmbh Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20020090646A1 (en) † 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
NZ522924A (en) 2000-05-26 2004-12-24 Ortho Mcneil Pharm Inc Neuroprotective peptides
CN1451013A (zh) 2000-09-01 2003-10-22 格莱风治疗公司 对亲核试剂稳定的硫酯生成化合物,及其生产和使用方法
US7138119B2 (en) * 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7405276B2 (en) 2000-11-01 2008-07-29 Elusys Therapeutics, Inc. Method of producing bispecific molecules by protein trans-splicing
WO2002089828A2 (fr) 2001-05-04 2002-11-14 Institute Of Molecular And Cell Biology Traitement de l'ischemie
US7419949B2 (en) * 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
US20030078180A1 (en) * 2001-10-24 2003-04-24 Benchmark Research & Technology, Inc. Contaminant-tolerant foaming additive
PL215168B1 (pl) * 2002-02-27 2013-10-31 Immunex Corp Formulacja polipeptydowa
AU2002316574B2 (en) † 2002-03-15 2008-05-01 Brandeis University Central airway administration for systemic delivery of therapeutics
NZ537306A (en) 2002-07-01 2008-11-28 Kenneth S Warren Inst Inc Compositions comprising mutein recombinant tissue protective cytokines having one or more amino acid substitutions facilitating transport of a molecule via transcytosis across an endothelial cell barrier
AU2003232081B2 (en) 2002-07-03 2009-02-05 Brandeis University Central airway administration for systemic delivery of therapeutics
US20040110929A1 (en) * 2002-07-12 2004-06-10 Bjorn Soren E. TF binding compound
AU2003242507A1 (en) * 2002-07-12 2004-02-02 Novo Nordisk A/S A tissue factor binding immunoconjugate comprising factor viia
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US20050281829A1 (en) * 2003-05-06 2005-12-22 Hehir Cristina A T Fc chimeric proteins with anti-HIV drugs
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
AU2004238263A1 (en) * 2003-05-06 2004-11-25 Syntonix Pharmaceuticals, Inc. Inhibition of drug binding to serum albumin
PT1624891E (pt) * 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
JP2007531513A (ja) 2003-11-13 2007-11-08 ハンミ ファーム．インダストリー カンパニー リミテッド 薬物のキャリアとして有用なＩｇＧＦｃ断片およびその製造方法
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
CA2546580A1 (fr) * 2003-11-18 2005-06-09 Iconic Therapeutics, Inc. Preparations homogenes de proteines chimeres
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
DK2729161T3 (en) * 2011-07-08 2019-04-08 Bioverativ Therapeutics Inc FACTOR VIII CHEMICAL AND HYBRID POLYPEPTIDES AND PROCEDURES FOR USE THEREOF
CN107531416B (zh) 2015-04-28 2020-08-21 佐藤控股株式会社 保管库

Also Published As

Publication number Publication date
CY1109640T1 (el) 2014-08-13
CY2016039I1 (el) 2017-03-15
CY2016039I2 (el) 2017-03-15
US8815250B2 (en) 2014-08-26
DK1624891T4 (da) 2013-07-15
PL1624891T5 (pl) 2014-02-28
PL2298347T3 (pl) 2016-03-31
AU2010201711B2 (en) 2012-04-05
ES2333598T5 (es) 2013-09-04
AU2004239244C1 (en) 2015-04-23
SI2298347T1 (sl) 2016-03-31
PT2077121E (pt) 2011-05-23
CA2522859C (fr) 2017-10-24
EP3002012A1 (fr) 2016-04-06
CA2522859A1 (fr) 2004-11-25
WO2004101740A2 (fr) 2004-11-25
CY1117090T1 (el) 2017-03-15
DK2077121T3 (da) 2011-06-06
SI1624891T1 (sl) 2010-01-29
ATE497783T1 (de) 2011-02-15
PL1624891T3 (pl) 2010-02-26
DE602004022800D1 (de) 2009-10-08
EP2298347A1 (fr) 2011-03-23
US20050147618A1 (en) 2005-07-07
EP3002012A9 (fr) 2016-11-16
EP1624891A2 (fr) 2006-02-15
HUS1600041I1 (hu) 2016-11-28
HUE026384T2 (en) 2016-06-28
AU2004239244A1 (en) 2004-11-25
PL2077121T3 (pl) 2011-07-29
SI1624891T2 (sl) 2013-09-30
US20180237762A1 (en) 2018-08-23
ES2333598T3 (es) 2010-02-24
US8449884B2 (en) 2013-05-28
SI2077121T1 (sl) 2011-07-29
ES2361036T3 (es) 2011-06-13
FR16C0041I1 (fr) 2016-09-12
ES2558102T3 (es) 2016-02-02
EP1624891B2 (fr) 2013-04-10
PT1624891E (pt) 2010-01-05
FR16C0041I2 (fr) 2019-07-05
CY1111725T1 (el) 2015-10-07
US20150044207A1 (en) 2015-02-12
US20130273047A1 (en) 2013-10-17
HK1153947A1 (en) 2012-04-20
EP2298347B1 (fr) 2015-09-30
AU2010201711C1 (en) 2012-11-08
EP2077121A1 (fr) 2009-07-08
WO2004101740A3 (fr) 2005-10-27
LU93265I2 (fr) 2016-12-19
US20110182896A1 (en) 2011-07-28
HK1134432A1 (en) 2010-04-30
DK1624891T3 (da) 2010-01-04
AU2010201711A1 (en) 2010-05-20
US20210348150A1 (en) 2021-11-11
EP1624891A4 (fr) 2007-06-06
EP1624891B1 (fr) 2009-08-26
PT2298347E (pt) 2016-01-29
DK2298347T3 (en) 2016-01-11
ATE440619T1 (de) 2009-09-15
EP2077121B1 (fr) 2011-02-09
DE602004031390D1 (de) 2011-03-24
EP3552627A1 (fr) 2019-10-16
NL300835I2 (fr) 2017-03-16
AU2004239244B2 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
BE2016C058I2 (fr)
UA95438C2 (ru) Биспецифические антитела, которые замещают функциональные белки
ZA200609407B (en) Monoclonal antibodies to hepatocyte growth factor
BE2016C015I2 (fr)
WO2002088170A3 (fr) Anticorps de blocage cripto et utilisations correspondantes
WO2007058823A3 (fr) Anticorps anti-egfr
EP2620450A3 (fr) Compositions d'anticorps anti-CTLA-4
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
ATE299510T1 (de) Peptide als kalium kanalaktivatoren
WO2004100882A3 (fr) Inhibition de medicament se liant a la serumalbumine